NASDAQ:NVNO enVVeno Medical (NVNO) Stock Price, News & Analysis $2.73 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.74 +0.00 (+0.18%) As of 04/25/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About enVVeno Medical Stock (NASDAQ:NVNO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get enVVeno Medical alerts:Sign Up Key Stats Today's Range$2.65▼$2.7750-Day Range$2.12▼$3.8252-Week Range$2.03▼$6.48Volume48,934 shsAverage Volume109,173 shsMarket Capitalization$47.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Read More… enVVeno Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreNVNO MarketRank™: enVVeno Medical scored higher than 18% of companies evaluated by MarketBeat, and ranked 757th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for enVVeno Medical. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for enVVeno Medical are expected to grow in the coming year, from ($1.32) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of enVVeno Medical is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of enVVeno Medical is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioenVVeno Medical has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about enVVeno Medical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.47% of the float of enVVeno Medical has been sold short.Short Interest Ratio / Days to CoverenVVeno Medical has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in enVVeno Medical has recently decreased by 3.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldenVVeno Medical does not currently pay a dividend.Dividend GrowthenVVeno Medical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.47% of the float of enVVeno Medical has been sold short.Short Interest Ratio / Days to CoverenVVeno Medical has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in enVVeno Medical has recently decreased by 3.98%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News Sentiment0.63 News SentimentenVVeno Medical has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for enVVeno Medical this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, enVVeno Medical insiders have not sold or bought any company stock.Percentage Held by Insiders16.00% of the stock of enVVeno Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.71% of the stock of enVVeno Medical is held by institutions.Read more about enVVeno Medical's insider trading history. Receive NVNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address NVNO Stock News HeadlinesenVVeno Medical Corp appoints CBIZ CPAs as new auditorApril 23 at 6:58 AM | investing.comenVVeno Medical reports FY24 EPS ($1.27) vs. ($1.91) last yearMarch 1, 2025 | markets.businessinsider.comM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).April 26, 2025 | Paradigm Press (Ad)enVVeno Medical files $100M mixed securities shelfMarch 1, 2025 | markets.businessinsider.comenVVeno Medical presents one-year data from VenoValve trialFebruary 20, 2025 | markets.businessinsider.comVenoValve trial shows sustained patient benefits at 24 monthsFebruary 7, 2025 | msn.comenVVeno Medical presents two-year follow-up data from VenoValve trialFebruary 7, 2025 | markets.businessinsider.comenVVeno Medical Corporation: enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVeDecember 16, 2024 | finanznachrichten.deSee More Headlines NVNO Stock Analysis - Frequently Asked Questions How have NVNO shares performed this year? enVVeno Medical's stock was trading at $3.02 at the beginning of the year. Since then, NVNO stock has decreased by 9.6% and is now trading at $2.73. View the best growth stocks for 2025 here. How were enVVeno Medical's earnings last quarter? enVVeno Medical Corporation (NASDAQ:NVNO) posted its earnings results on Thursday, February, 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. Who are enVVeno Medical's major shareholders? Top institutional shareholders of enVVeno Medical include Westside Investment Management Inc. (1.48%). Insiders that own company stock include Robert Andrew Berman, Francis Duhay, Matthew Jenusaitis, Robert Gray, Sanjay Shrivastava and Hamed Alavi. View institutional ownership trends. How do I buy shares of enVVeno Medical? Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of enVVeno Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that enVVeno Medical investors own include Bionano Genomics (BNGO), VBI Vaccines (VBIV), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Amarin (AMRN), Coherus BioSciences (CHRS) and Exelixis (EXEL). Company Calendar Last Earnings2/27/2025Today4/26/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVNO CIK1661053 Webwww.hancockjaffe.com Phone(949) 261-2900Fax949-261-2992Employees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-48.72% Return on Assets-45.96% Debt Debt-to-Equity RatioN/A Current Ratio22.01 Quick Ratio22.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.47 per share Price / Book0.79Miscellaneous Outstanding Shares17,536,000Free Float14,730,000Market Cap$47.87 million OptionableOptionable Beta1.04 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NVNO) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enVVeno Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share enVVeno Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.